Drugs / Tositumomab
Tositumomab
Trials 21 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT00777114 | Apr 2007 → Dec 2012 | non-Hodgkin lymphoma | Weill Medical College of Cornell University | Completed | No outcome recorded |
| Phase 1 | NCT00434629 | Feb 2007 → May 2015 | B-cell non-Hodgkin lymphoma | University of Pennsylvania | Completed | No outcome recorded |
| Phase 1 | NCT00315731 | Mar 2003 → Dec 2006 | follicular lymphoma | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT01536561 | Apr 1990 → Jul 1997 | non-Hodgkin lymphoma | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 215 trials | ||||||
| Phase 2 | NCT00770224 | Apr 2009 → Apr 2017 | lymphoma | SWOG Cancer Research Network | Completed | No outcome recorded |
| Phase 2 | NCT00475332 | Sep 2007 → Apr 2009 | follicular lymphoma | University of Florida | Terminated | No outcome recorded |
| Phase 2 | NCT00476047 | Feb 2007 → Feb 2015 | chronic lymphocytic leukemia/small lymphocytic lymphoma | Fred Hutchinson Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT00490490 | Jan 2007 → Jun 2011 | non-Hodgkin lymphoma | Stanford University | Terminated | No outcome recorded |
| Phase 2 | NCT00577629 | Jun 2005 → Apr 2012 | B-cell non-Hodgkin lymphoma | Duke University | Completed | No outcome recorded |
| Phase 2 | NCT00240565 | Apr 2004 → Feb 2007 | non-Hodgkin lymphoma | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT00992992 | Jun 2001 → Jun 2013 | mantle cell lymphoma | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT01868035 | May 2000 → Oct 2012 | non-Hodgkin lymphoma | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT01663714 | Feb 2000 → Feb 2012 | non-Hodgkin lymphoma | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT00268203 | Sep 1998 → Mar 2000 | non-Hodgkin lymphoma | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT00933335 | Aug 1998 → Dec 2009 | non-Hodgkin lymphoma | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT00996593 | Jul 1998 → Apr 2001 | non-Hodgkin lymphoma | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT00950755 | Jun 1998 → Apr 2011 | non-Hodgkin lymphoma | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT00989664 | Nov 1996 → Jan 2004 | non-Hodgkin lymphoma | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT01224821 | Dec 1995 → Nov 1997 | non-Hodgkin lymphoma | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT00268983 | Oct 2004 → Sep 2009 | B-cell non-Hodgkin lymphoma | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00078598 | Apr 2004 → ? | non-Hodgkin lymphoma | Corixa Corporation | Unknown | No outcome recorded |
Also used as a comparator or background therapy in 3 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01573000 Background | Sep 1998 → Apr 2001 | non-Hodgkin lymphoma | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT00938041 Background | Apr 1998 → May 2003 | non-Hodgkin lymphoma | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT00996996 Background | Jun 1996 → Mar 1999 | B-cell non-Hodgkin lymphoma | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 24 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tositumomab | “Patients will receive an infusion of unlabeled Tositumomab (450 mg) immediately followed by an infusion of the patient specific dose of tellurium-derived Iodine I 131...” NCT00315731 ↗23“Subjects were randomized to receive either tositumomab (Anti-B1 Antibody) and iodine I 131 tositumomab (Arm A) or unlabeled tositumomab (Arm B).” NCT01573000 ↗ “Bexxar (Tositumomab and 131I Tositumomab) radioimmunotherapy” NCT00434629 ↗ |
| Known as | Anti-B1 | “131-I anti-B1 is the product of 131-I labeling of the anti-CD20 murine monoclonal antibody and the anti-B1 antibody itself is an intact IgG2a murine monoclonal antibody which...” NCT01536561 ↗ |
| Known as | Anti-B1 Antibody | “Subjects were randomized to receive either tositumomab (Anti-B1 Antibody) and iodine I 131 tositumomab (Arm A) or unlabeled tositumomab (Arm B).” NCT01573000 ↗2“Tositumomab and Iodine I 131 Tositumomab (Anti-B1 Antibody and Iodine-131 Anti-B1 Antibody)” NCT00996996 ↗ “450 milligrams (mg) of unlabeled tositumomab (TST, Anti-B1 Antibody) intravenously (IV)” NCT01224821 ↗ |
| Known as | Bexxar | “This is a single arm, multi-center, expanded access study of Iodine I 131 Tositumomab (BEXXAR) therapeutic regimen for patients with relapsed or refractory low-grade or...” NCT00268203 ↗ |
| Known as | Iodine I 131 Tositumomab | “This is a single arm, multi-center, expanded access study of Iodine I 131 Tositumomab (BEXXAR) therapeutic regimen for patients with relapsed or refractory low-grade or...” NCT00268203 ↗ |
| Known as | TST | “450 milligrams (mg) of unlabeled tositumomab (TST, Anti-B1 Antibody) intravenously (IV)” NCT01224821 ↗1“Tositumomab and Iodine I 131 Tositumomab (TST/I-131 TST)” NCT00989664 ↗ |
| Modality | Monoclonal antibody | “Monoclonal antibodies, such as tositumomab and iodine I 131 tositumomab” NCT00476047 ↗ |
| Route | Intravenous | “a 20 min IV infusion of 35 mg TST labeled with I 131” NCT00240565 ↗ |